Summit Therapeutics Inc.
SMMT · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2018–FY2025
- History
- 8 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Summit Therapeutics Inc. at a glance
In FY2025, Summit Therapeutics Inc. reported EBITDA of USD -1,094,278 thousands, free cash flow of USD -323,587 thousands.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| EBITDA | -210,902 | -1,094,278 | |||
| Free cash flow | -142,245 | -323,587 |
The full 8-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas